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stool samples (an early sign of CRC); flexible sigmoidoscopy (FS), which involves visual inspection of the distal bowel for polyps and cancers; and total colonoscopy (TC), which visualizes the entire bowel and therefore is a more invasive examination.
Biennial screening using a guaiac FOBt (gFOBt) was found to decrease mortality by 15% after 13 years of follow-up in a large randomized trial in Funen, Denmark, 4, 5 and by 13% after an 11-year follow-up in Nottingham, United Kingdom. 6, 7 Neither study found a decrease in incidence, although follow-up continues. A more complex trial in Minnesota, USA, compared annual and biennial screening using FOBt. 8 After an 18-year follow-up, mortality decreased by 33% in participants screened annually, and 21% in those screened biennially. 9 Reductions in incidence of 20% and 17% were also observed for annually and biennially screened individuals, respectively. 10 Four large-scale randomized clinical trials are evaluating FS as a screening tool. Baseline findings have been published showing that FS screening is safe (no major complications and relatively few perforations) and acceptable to the population. [11] [12] [13] [14] [15] A randomized clinical trial of FS screening in Telemark, Norway reported an 80% reduction in CRC incidence rates with a 13-year follow-up. The numbers in this study were small, however. 16 Although TC detects adenomas beyond the reach of FS no randomized clinical trials have been conducted. However, the U.S. National Polyp Study reported a reduction in the incidence of CRC when comparing those who had a complete colonoscopy where all adenomas were removed, to 3 reference groups: patients with polyps 1 cm who declined to undergo surgery; patients who had all rectal adenomas removed; and the final cohort was a sample of the general population. 17 A country's screening initiatives need to be adapted to suit its population size, health care system and methods of funding. However, it will be beneficial to collect and share implementation and performance data among countries. Information on the effectiveness of technologies and methodologies can benefit existing programs. It can also provide insights and guidance to those in the planning stages of screening initiatives. Additionally, comparing the effectiveness of different screening modalities within a country could inform decision-making about an appropriate national screening protocol specific to the needs of that country. To facilitate the sharing of such information and comparisons, it is important to have a common nomenclature and for initiatives to be collecting the appropriate data. However, because colorectal screening is in its infancy in most countries, a common language to describe the screening process and common measures by which quality can be examined for all tests and types of programs have yet to be established.
In June 2002, the International Union Against Cancer and the American Cancer Society sponsored an international workshop in Oslo, Norway, on facilitating screening for CRC. 18 From this meeting it was clear that a great deal of CRC screening activity was taking place worldwide, and that it would be beneficial to describe the activity and build a network to share experience and knowledge. Subsequently, the Centers for Disease Control and Prevention and the American Cancer Society supported a collaborative effort with Cancer Research UK to develop the International Colorectal Cancer Screening Network (ICRCSN).
The first aim of the ICRCSN was to identify and document the status of organized screening initiatives, and that information is reported in the present article. As a next step, the ICRCSN is focused on establishing a consensus minimum set of screening program descriptors and quality assurance measures with common definitions and measurement metrics to enable program evaluation and comparisons.
Methods
Known colorectal screening initiatives in progress (either screening or in follow-up after screening) as of May 2004 were contacted to assess their interest and potential for involvement in the ICRCSN. Initial approaches were made through personal knowledge of grant holders, conference contacts and literature and internet searches. Each contact was asked to identify other initiatives. The lead of each initiative was identified and a working group, composed of 11 members from 5 countries, was convened to develop the methodology and principles for the survey.
To be included in the Network, screening initiatives were required to meet a set of criteria. Initiatives were required to be carrying out screening of the general population, targeting asymptomatic people within a defined age range, and in an organized manner, as defined by the International Agency for Research on Cancer (IARC). 19 Characteristics of an organized screening program include an explicit policy with specified age categories, method and interval for screening; a defined target population; a management team responsible for implementation; a health care team for decisions and care; a quality assurance structure; and a method for identifying cancer occurrence in the target population. Initiatives were further classified as (i) programs in which screening is offered as part of routine health care; (ii) pilot studies carried out in a limited population for a limited time to assess feasibility, with a view to possibly extending to a program, or (iii) research projects with a fixed sample size and duration aimed at answering a specific question. If an initiative used more than 1 screening modality, then each modality (or combination of modalities offered to the same participant) was considered a separate activity.
Between November 2003 and March 2004, 2 questionnaires were designed to elicit information about screening initiatives in the countries and regions represented by members of the ICRCSN. The questionnaires were patterned after instrumentation developed by the International Breast Cancer Screening Network to characterize breast cancer screening activities among participating countries (http://appliedresearch.cancer.gov/ICSN/). The first questionnaire, the National Questionnaire, asked about a country's policies and guidelines on CRC screening, as well as for specific information about screening initiatives. The questionnaire included details of modality, target population and some information about protocol.
In addition to the National Questionnaire, modality-specific questionnaires were designed for FOBt, FS and TC. The questionnaires contained 6 sections: contact details for activity leads and other individuals involved in the activity, screening methodology, testing details, status of the initiative/activity, screening performance and outcomes and quality assurance.
Drafts were reviewed by a subgroup of the working group and pilot tested with a sample of initiative representatives of the ICRCSN. The finalized questionnaires were distributed in March 2004 via email to representatives from all known initiatives.
An international workshop for survey respondents was held in London in May 2004. Results of the survey were described and discussed. Areas requiring classification or confirmation were identified and refinements made. Unclear responses to the questionnaire were clarified by subsequent communications with the initiative leads.
Results
A total of 35 organized independent initiatives delivering CRC screening to asymptomatic populations were identified. These were then analyzed by geographic location, screening modality and type of initiative.
Geographical variation
The 35 organized initiatives were identified in 17 countries in 3 geographic regions (as defined by the World Health Organization, or by proximity where necessary): Europe (n 5 23), the Americas (n 5 6) and the Western Pacific (n 5 6) ( Table I) . Initiatives were funded primarily by public funds, usually from central and local governments. Forty-six percent of the initiatives were funded only by government funds, and 31% were funded by the government and at least one other source. Initiatives were funded to a lesser extent by charities, health insurance and self-funding. A very small contribution came from industry or other private sources.
Modality analysis
We gathered information on 3 screening modalities: FOBt (Table IIa), FS (Table IIb) and TC (Table IIc) . Seven initiatives used more than 1 modality or combination of modalities. Due to different protocols, each activity was described separately, which resulted in 45 activities overall.
Of the 45 activities, 22 were using FOBt only. In addition, 2 research projects, 1 in Norway and 1 in Switzerland, used FOBt in combination with FS. Fourteen were using a gFOBt only, 9 used a fecal immunochemical test (FIT) only and 1, an Australian research project, used both types. Fourteen of the FOBt activities used biennial screening, 8 screened annually, and 2 screened once only during the study period.
The age groups of the target populations varied widely. Although all FOBt activities included adults aged 59-64 years, some enrolled participants in their 40s. Some activities had no upper age limit, while others ended recruitment between ages 64 and 80. Dietary restriction was common for those using gFOBt, with counseling to remove vitamin C, red meats and nonsteroidal anti-inflammatory drugs from the diet prior to stool samples being taken. Every activity used colonoscopy for investigation after a positive FOBt result. The definition of a positive test varied. For example, some activities recorded a participant as positive if 1 or more test squares were positive on the FOBt card (pilot studies in particular). Other activities deemed a participant as positive if 5 or more squares on multiple cards were positive.
Fourteen of the initiatives were using FS only as their screening modality. In addition, 1 initiative in Norway and 1 in Switzerland used FS in combination with FOBt. Nine of these 16 activities were ''once only'' screening, although whether this was offered at a particular age (58 or 60 years old) or to an age range (50-64 years old) varied. Six of the activities offered screening every 5 years; one, the Colon Cancer Prevention Program (CoCaP) in Northern California, offered screening every 10 years. Many of the activities used a home-based enema administered by the patient as their bowel preparation, whereas Australia, Norway and Switzerland routinely used enemas in the screening unit. The CoCaP also used laxatives as part of its bowel preparation.
Nurses performed endoscopy in a program in Ontario, Canada and a research study in the United Kingdom. Nurses, gastroenterologists or primary care practitioners performed endoscopy in the U.S. Prostate, Lung, Colon and Ovarian (PLCO) cancer screening trial and the CoCaP program. Elsewhere, gastroenterologists and (to a lesser extent) surgeons performed the procedure.
Most activities had clear protocols for polyp removal and criteria for referral for a colonoscopy. In Australia (the pilot study), Belgium, Canada, Norway, Switzerland and the U.S. PLCO trial, polyps were not removed during FS and patients were referred for colonoscopy.
Six activities used colonoscopy as a screening technique; 3 on a once-only basis, 1 at 5-year intervals, and 2 at 10-year intervals. All colonoscopy activities offered screening to participants aged 55-64; however, the age at screening ranged from 50 to 80, depending on the activity. Colonoscopies were routinely conducted in the hospital, except in the Swiss research project (in which they also were carried out in a doctor's office) and in the In combination with fecal occult blood tests.
U.S. National Colonoscopy Study (in which colonoscopies were performed in an outpatient endoscopy unit). In all studies, gastroenterologists performed the screening colonoscopy. In Poland, surgeons were also able to perform colonoscopy.
Initiative designs
Ten routine population screening programs were identified in 7 countries. Eight countries (9 initiatives) were running pilot studies, and research projects continued in 11 countries (16 initiatives). Italy was running a number of different local programs, rather than a single national program. Research projects coexisted in countries that were operating pilot projects or full programs.
Programs
Five of the identified programs offered FOBt only, 3 offered FS only, 1 offered TC only and 1 program in Italy (Prevenzione Serena) offered both FOBt and FS (Table IIIa) . The most established programs were in Japan and Israel, as well as CoCaP in the United States. These programs began recruitment in 1992, 1993 and 1994, respectively. A variety of recruitment methods were used; a mailed invitation, usually personalized, was the most popular method where population registers were available. Other methods included referral by a family practitioner and the use of media. Practice varied as to whether the written results were sent to the patient, the patient's usual family physician, or both. All programs had mechanisms to follow up all positive FOBt or FS results, except for the Czech Republic and the CoCaP program. All programs had evaluation systems in place.
Pilot studies
Seven of the identified pilot projects offered FOBt, 1 offered FS and 1 in Italy (SCORE 2) offered both (Table IIIa ). All 9 projects had some form of population register available, and systems in place for invitations and reminders (except for Canada, the U.S. Veterans Affairs (VA) pilot study and Taiwan). All studies had structured systems in place for evaluations, and 7 sent the results to both the patient and their usual doctor. The exceptions were Canada (only the patient's doctor received the results) and Taiwan (only the patient received the results). Canada, the U.S. VA pilot study and Taiwan had no mechanisms to follow up a positive test.
Research projects
Four of the identified research projects offered FOBt only, 5 offered FS only, 2 offered TC only and 5 offered a combination of 2 or 3 modalities (Table IIIa) . Half of the population in the Norwegian study received FOBt screening in combination with FS. All except Hong Kong used some form of population register for recruitment. In addition, the majority of the initiatives had systems in place for evaluation, as well as routinely sending reminders to nonresponders. All projects reported normal and abnormal results to the patients. Eleven also reported normal results to physicians; 13 reported abnormal results to physicians.
Most of the projects were randomized controlled trials. Switzerland and Hong Kong described their studies as cohort studies; Belgium and the nurse-led study in the United Kingdom were described as feasibility studies (Table IIIb) . It was in these initiatives that the greatest mix of protocols was found, with various combinations of modalities being used.
Discussion
The publication during the early and mid 1990s of trial and study results demonstrating the efficacy of screening for CRC had led, by the early years of the 21st century, to the implementation of a number of diverse screening initiatives in several countries of the world, in particular those with a high incidence of CRC. This is the first investigation describing the delivery of screening protocols to various populations.
Of the 17 countries identified by the ICRCSN that had begun organized CRC screening prior to May 2004, only 4 provided national programs. Three of these programs offered FOBt (Czech Republic, Israel and Japan) as their screening modality; one, Poland, offered TC. Six other programs (4 in Italy) were offered only at a regional level. In addition, there were 4 central government-funded pilot studies reported (France, United Kingdom, United States and Australia), most of which have subsequently progressed into national programs [France, United Kingdom (http://www.cancerscreening.nhs.uk/bowel/index.html) and the U.S. VA program]. Several of the other pilot studies had local government funding and may advance to regional programs in the future.
Fecal occult blood testing was the most frequently used screening modality, possibly because of the encouraging results in terms of acceptability, feasibility and efficacy from previous randomized clinical trials. 4, 6, 8 In 1999, FOBt was accepted by the European Union as the standard for CRC screening. 20 Several initiatives have used protocols based on those from the randomized clinical trials (for example, timing of screening, use of gFOBt, taking 2 samples from 3 consecutive bowel movements and dietary restriction). Some more recent FOBt initiatives have used FIT rather than gFOBt.
FS also was frequently used. Although large clinical trials of FS screening do exist (none are completed), they are more recent than those using FOBt, and there are fewer, if any, initiatives following trial protocols. 11, 12, 14, 15 Bowel preparation for FS screening was fairly uniform, in that every participant had an enema that was typically self-administered at home. Screening typically occurred only once, but 5-year and 10-year intervals also were used. Referral for colonoscopy varied from any polyp being identified to criteria based on the number, size and histopathology of polyps found through FS.
TC was used in only 6 initiatives (1 program and 5 research projects), even though it is considered the ''gold standard'' for CRC identification. Gastroenterologists always performed TC, except in Poland where surgeons also performed the procedure. Colonoscopies were conducted in a hospital for all initiatives, as well as in the office of the gastroenterologist in Switzerland and in an outpatient endoscopy unit in the United States. Once-only screening was most common, however, 5-year screening was conducted in Hong Kong, and 10-year screening in Poland and Switzerland.
At this stage there appears to be no preferred method of conducting CRC screening, defining a positive screening test for purposes of initiating follow-up, and for follow-up itself. Information was collected in the survey on screening performance and outcomes and quality assurance measures; however, because of the lack of standardized definitions, more information is required on these topics before conclusions can be drawn. Consequently, continued activity for the ICRCSN will concentrate on the development of quality assurance protocols and indicators to allow commonly understandable results to be reported across all participants in the Network.
Unfortunately, not all organized CRC screening initiatives in existence in 2003/2004 were included in this report. Some initiatives were not brought to the attention of the ICRCSN until after data collection. We will continue to include initiatives as they are identified.
In conclusion, the knowledge gained from programs, research projects and pilot studies can be shared and used in the advancement of CRC screening. The establishment of the ICRCSN has made the sharing of valuable information possible and has created a connection among initiatives across the world. It is the intention that preferred protocols will be established in the future, establishing uniform screening methodologies and guidelines that can be followed by future initiatives. The continued support of the Network's members will help both new and existing initiatives reach their full potentials. 
